New Search

Export article
Open Access

Seropositivity for Helicobacter pylori and hepatobiliary cancers in the PLCO study

Rishi Makkar, Julia Butt, Wen-Yi Huang, Katherine A. McGlynn, Jill Koshiol, Michael Pawlita, Tim Waterboer, , Gwen Murphy
British Journal of Cancer , Volume 123, pp 909-911; doi:10.1038/s41416-020-0961-0

Abstract: Helicobacter has been suggested to play a possible role in hepatitis, gallstones, and hepatobiliary tumours. We assessed whether seropositivity to 15 H. pylori proteins was associated with subsequent incidence of 74 biliary tract and 105 liver cancer cases vs. 357 matched controls in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). Odds ratios and 95% confidence intervals were computed by conditional logistic regression after adjustment for known hepatobiliary cancer risk factors. H. pylori seropositivity was not associated with either biliary tract (1.76, 0.90–3.46) or liver cancer (0.87, 0.46–1.65). CagA seropositivity was associated with both endpoints, although the latter association was not statistically significant (biliary tract: 2.16, 1.03–4.50; liver cancer: 1.96, 0.98–3.93) and neither association was statistically significant after correcting for multiple comparisons. Together, these results suggest possible associations between H. pylori and hepatobiliary cancer and suggest the value of future studies investigating the association.Trial registration number: NCT00339495.
Keywords: proteins / helicobacter / Plco / Seropositivity / pylori and hepatobiliary cancer

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

Share this article

Click here to see the statistics on "British Journal of Cancer" .
References (19)
    Back to Top Top